Of interest, the non-covalent KRAS<sup>G12D</sup> targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside. This evidence concerns the gene KRAS and familial pancreatic carcinoma.